Literature DB >> 18541899

Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival.

Daniel A Hamstra1, Craig J Galbán, Charles R Meyer, Timothy D Johnson, Pia C Sundgren, Christina Tsien, Theodore S Lawrence, Larry Junck, David J Ross, Alnawaz Rehemtulla, Brian D Ross, Thomas L Chenevert.   

Abstract

PURPOSE: Assessment of radiologic response (RR) for brain tumors utilizes the Macdonald criteria 8 to 10 weeks from the start of treatment. Diffusion magnetic resonance imaging (MRI) using a functional diffusion map (fDM) may provide an earlier measure to predict patient survival. PATIENTS AND METHODS: Sixty patients with high-grade glioma were enrolled onto a study of intratreatment MRI at 1, 3, and 10 weeks. Receiver operating characteristic curve analysis was used to evaluate imaging parameters as a function of patient survival at 1 year. Both log-rank and Cox proportional hazards models were utilized to assess overall survival.
RESULTS: Greater increases in diffusion in response to therapy over time were observed in those patients alive at 1 year compared with those who died as a result of disease. The volume of tumor with increased diffusion by fDM at 3 weeks was the strongest predictor of patient survival at 1 year, with larger fDM predicting longer median survival (52.6 v 10.9 months; log-rank, P < .003; hazard ratio [HR] = 2.7; 95% CI, 1.5 to 5.9). Radiologic response at 10 weeks had similar prognostic value (median survival, 31.6 v 10.9 months; log-rank P < .0007; HR = 2.9; 95% CI, 1.7 to 7.2). Radiologic response and fDM differed in 25% of cases. A composite index of response including fDM and RR provided a robust predictor of patient survival and may identify patients in whom RR does not correlate with clinical outcome.
CONCLUSION: Compared with conventional neuroimaging, fDM provided an earlier assessment of equal predictive value, and the combination of fDM and RR provided a more accurate prediction of patient survival than either metric alone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541899      PMCID: PMC3266717          DOI: 10.1200/JCO.2007.15.2363

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  47 in total

1.  Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy.

Authors:  Kuei C Lee; Bradford A Moffat; Anne F Schott; Rachel Layman; Steven Ellingworth; Rebecca Juliar; Amjad P Khan; Mark Helvie; Charles R Meyer; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

2.  Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations.

Authors:  C R Meyer; J L Boes; B Kim; P H Bland; K R Zasadny; P V Kison; K Koral; K A Frey; R L Wahl
Journal:  Med Image Anal       Date:  1997-04       Impact factor: 8.545

3.  Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.

Authors:  Victor D Schepkin; Kuei C Lee; Kyle Kuszpit; Mukilan Muthuswami; Timothy D Johnson; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  NMR Biomed       Date:  2006-12       Impact factor: 4.044

4.  Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy.

Authors:  L D Stegman; A Rehemtulla; D A Hamstra; D J Rice; S J Jonas; K L Stout; T L Chenevert; B D Ross
Journal:  Gene Ther       Date:  2000-06       Impact factor: 5.250

5.  Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging.

Authors:  D Le Bihan; E Breton; D Lallemand; M L Aubin; J Vignaud; M Laval-Jeantet
Journal:  Radiology       Date:  1988-08       Impact factor: 11.105

6.  Response and progression in recurrent malignant glioma.

Authors:  K R Hess; E T Wong; K A Jaeckle; A P Kyritsis; V A Levin; M D Prados; W K Yung
Journal:  Neuro Oncol       Date:  1999-10       Impact factor: 12.300

7.  Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results.

Authors:  Yoshiko Hayashida; Toshitake Yakushiji; Kazuo Awai; Kazuhiro Katahira; Yoshiharu Nakayama; Osamu Shimomura; Mika Kitajima; Toshinori Hirai; Yasuyuki Yamashita; Hiroshi Mizuta
Journal:  Eur Radiol       Date:  2006-08-15       Impact factor: 5.315

8.  Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

Authors:  Daniel A Hamstra; Thomas L Chenevert; Bradford A Moffat; Timothy D Johnson; Charles R Meyer; Suresh K Mukherji; Douglas J Quint; Stephen S Gebarski; Xiaoying Fan; Christina I Tsien; Theodore S Lawrence; Larry Junck; Alnawaz Rehemtulla; Brian D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-02       Impact factor: 11.205

9.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.

Authors:  June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

10.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506

View more
  131 in total

Review 1.  Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.

Authors:  Wolfgang Wick; Antje Wick; Markus Weiler; Michael Weller
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

2.  Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Taryar Zaw; Albert Lai; Phioanh L Nghiemphu; Robert Harris; Shadi Lalezari; Naveed Wagle; Kourosh M Naeini; Jose Carrillo; Linda M Liau; Whitney B Pope
Journal:  Neuro Oncol       Date:  2012-01-22       Impact factor: 12.300

Review 3.  Clinical applications of imaging biomarkers. Part 3. The neuro-oncologist's perspective.

Authors:  A Shenoy
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 4.  Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy.

Authors:  Anwar R Padhani; Aftab Alam Khan
Journal:  Target Oncol       Date:  2010-04-11       Impact factor: 4.493

Review 5.  Applications of molecular imaging.

Authors:  Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

6.  Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy.

Authors:  Reza Farjam; Christina I Tsien; Felix Y Feng; Diana Gomez-Hassan; James A Hayman; Theodore S Lawrence; Yue Cao
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

7.  Effects of perfusion on diffusion changes in human brain tumors.

Authors:  Alexander D Cohen; Peter S LaViolette; Melissa Prah; Jennifer Connelly; Mark G Malkin; Scott D Rand; Wade M Mueller; Kathleen M Schmainda
Journal:  J Magn Reson Imaging       Date:  2013-02-06       Impact factor: 4.813

Review 8.  MRI-only treatment planning: benefits and challenges.

Authors:  Amir M Owrangi; Peter B Greer; Carri K Glide-Hurst
Journal:  Phys Med Biol       Date:  2018-02-26       Impact factor: 3.609

9.  Image registration for quantitative parametric response mapping of cancer treatment response.

Authors:  Jennifer L Boes; Benjamin A Hoff; Nola Hylton; Martin D Pickles; Lindsay W Turnbull; Anne F Schott; Alnawaz Rehemtulla; Ryan Chamberlain; Benjamin Lemasson; Thomas L Chenevert; Craig J Galbán; Charles R Meyer; Brian D Ross
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

Review 10.  Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients.

Authors:  John H Rossmeisl; Paulo A Garcia; Gregory B Daniel; John Daniel Bourland; Waldemar Debinski; Nikolaos Dervisis; Shawna Klahn
Journal:  Vet Radiol Ultrasound       Date:  2013-11-13       Impact factor: 1.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.